By the end of 2022, the global automated cell biology systems market is anticipated to be worth US$ 14.1 Billion, and it will grow at a CAGR of 9.0% to reach an expected valuation of around US$ 33.5 Billion by the year 2032. Infinite cell line cultures dominate the worldwide market in 2021, with a share of around 76.2%, according to a recent analysis by Future Market Insights.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 14.1 Billion |
| Market Value 2032 | US$ 33.5 Billion |
| CAGR 2022 to 2032 | 9.0% |
| Market Share of Top 5 Countries | 62.3% |
| Key Market Players | Thermo Fisher Scientific, Corning Incorporated, Merck KGaA, Lonza, Sartorius AG, Hitachi. Ltd, Nanoentek, ChemoMetec, Danaher Corporation, Agilent Technologies, Perkin Elmer (Nexcelom Bioscience LLC.), F. Hoffmann-La Roche AG, SHIMADZU CORPORATION, Bio-Rad Laboratories, Miltenyi Biotec, Sinfonia Technology, SHIBUYA CORPORATION, Advanced Instruments, Cell Culture Company, LLC, BD, and Hamilton Company |
Compared to the widespread methods utilized in the second half of the twentieth century, modern cell cultivation techniques are not significantly different. Despite the fact that these techniques made it possible to comprehend a variety of biological processes and that they served as determining factors for applications like drug testing and tissue regeneration, they had a number of inherent drawbacks. In actuality, conventional cell culture systems necessitate numerous and intricate manual handling techniques, which restricts the consistency of the cultivation in terms of cell yield and activity.
Additionally, long-term cell maintenance is costly, time-consuming, and demands a lot of reagents, test samples, and work. By reducing the number of operator interventions, the shift to user-friendly automated devices would favor standardizing the cultivation process, cutting production costs, and shortening the time required for cell culture preparation, thus promoting market growth for automated cell biology systems.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for automated cell biology systems was approximately 65.8% of the overall ~US$ 19.9 Billion global bioprocess technology market in 2021.
The sale of automated cell biology systems expanded at a CAGR of 6.6% from 2015 to 2021.
Technologies like microfluidics and lab-on-a-chip represent a strategic approach to support the shift to user-friendly automated equipment. By using microculture systems in place of conventional Petri plates and flasks for cellular tests, researchers have been able to minimize the number of reagents used while still achieving high-throughput cell generation and culture in a controlled setting.
The development of tissue engineering aims to increase the possibility of replacing tissue development for regenerating or restoring organ and tissue function. Tissue engineering technology has advanced significantly in recent years, and it is now widely used in domains other than medicine, such as organs-on-a-chip, bioelectronic devices, cultured meats, and so on.
Cell culture is the primary method used for tissue engineering manufacturing. Therefore, it is crucial for tissue engineering research to maintain high standards for cell culture settings.
Modern uses of analytical system automation include clinical, pharmacological, and biomedical environments. The automatic system has played a significant role in both qualitative and quantitative analysis. Optically driven, electrochemical, and mass spectroscopic approaches have all been used as analytical techniques. Robotic automation lowers the cost of analysis while providing high precision and high system throughput.
Numerous lab-on-chip advancements have been made for cell culture and certain other biomedical applications. A cell culture device indicates the viability of the cells, nutrient consumption, nutrient output in the fermentation process, and pharmacological effect.
Because of the aforementioned factors, it is anticipated that from 2022 to 2032, the global automated cell biology systems market will expand at a CAGR of 9.0%.
As automated cell culture, on-chip is widely acknowledged as a benchmark parameter in existing microfluidic systems for cell biology, and a plethora of studies have been documented in the literature. At the research laboratory level, the minimization and downsizing of additional peripheral equipment are considered a fundamental necessity for the utilization of automated devices in cell culture, coupled with the need for systems that are ready-to-use in a plug-and-play mode.
Currently, the use of micro-devices for fluidic control is limited to the use of relatively complicated, specialized, and bulky external equipment and macro-to-micro interface systems, necessitating the ongoing assistance of human operators to manage fluid flow in an unstandardized and manual manner.
The systematic application of a suitably integrated control system for accurate fluid handling in a remote control framework will significantly improve the usability and readout dependability of micro-bioreactors. This is crucial in automating cell culture techniques, reducing human involvement, and significantly lowering the number of connection tubes, intake and output ports, and bulky external equipment.
The adoption of such control systems is gaining traction, owing to the above-mentioned factors, and this is set to pose lucrative opportunities for growth within the global automated cell biology systems market during the forecasted years.
Principal Consultant
Cell-based therapies have the ability to provide a successful treatment for medical disorders that are presently incurable. Their widespread commercialization has been put at risk by constraints such as scaling up and automating labor-intensive research discoveries, high production costs, and batch variance in large-scale automated manufacturing.
Additionally, even though many cell culture labs employ automated tools to do away with manual duties like handling plates, highly-trained lab staff are still required to spend hours every day maintaining these devices. As a result, the majority of benchtop automation has limitations in terms of scaling in cell culture facilities.
Furthermore, the utilization of mammalian cell culture is quickly expanding. Even though the fundamental processes for sustaining cells are quite repeatable, the majority of cell culture operations are still done by hand.
Personnel is required to perform repetitive tasks for hours on end each day, and frequently they must come in after regular working hours to cater to the cells or modify their biology to accommodate the workload. Both the workflow's throughput and its ability to be tracked are limited by this dependence on manual steps.
With the above-mentioned factors, the market for automated cell biology systems experiences a restraint in growth.
With a market share of 89.8% in all of North America in 2021, the USA presently dominates the region and is expected to sustain this growth throughout the forecast period.
The increasing expenditure on Research and Development in the area can be attributed to the market's expansion. Additionally, the expansion of pharmaceutical firms and manufacturers in the area together with rising public awareness of stem cell therapy is anticipated to significantly contribute to the market's expansion. Additionally, it is predicted that the rising number of bone marrow and cord blood transplants across the region will favorably influence market growth.
China represents roughly 64.9% of the East Asia market in 2021, with growth at a lucrative CAGR of 13.7% throughout the forecast period. China has a significant demand for automation, according to the International Federation of Robotics (IFR). According to sales volume, China was one of the top five markets for industrial robots in 2015.
The China Robot Industry Alliance estimates that Chinese robot suppliers sold about 20,400 units in 2015, increasing their share of the global market from 25% to 29% from 2013 until 2015. With the growing wave in automation, as well as its adoption, China is posed to be a highly lucrative market for automated cell biology systems over the forecast period.
During the forecast years, Germany is projected to grow at a CAGR of nearly 7.2% in the global automated cell biology systems market. The European Medicinal Agency (EMA) granted the CliniMACS Prodigy platform approval for the commercial manufacturing process in 2018 for the customization of protocols, which is accomplished through modularity and flexible programming, allowing its use for a number of different cell types, including the development of CAR-T cells, macrophages, virus-specific T-cells, and dendritic cells. With the manufacturing of such capable platforms, Germany is set to aid with the growth of the overall market during the projected period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Automated cell counters (single function) are the leading segment as a product, hold approximately 34.6% market share in 2021, and are expected to present high growth at a CAGR of 8.1% throughout the forecast period. The benefit of using an automated cell counter is that it largely eliminates human bias from the cell counting process. They can count more cells and are frequently faster than manually counting, which improves statistical accuracy. Automated cell counters are also employed in research and clinical labs. They can be used on urine and blood samples to count the different cell types present or to evaluate the viability of a cultivated cell line for investigation.
Infinite cell line cultures hold a global market share of around 76.2%, in 2021. Infinite cell line cultures are more robust and convenient to work with than primary cells since they can reproduce indefinitely. Infinite cell line cultures are also convenient for researchers because they are less expensive, easier to use, and able to survive more stages than primary cells. Because cell lines have a limitless supply of material and are simple to alter and grow, they are preferred for multiple screenings.
Drug development holds a share of around 35.4% in 2021, and this segment is expected to display gradual growth over the forecast period. New scientific developments in basic research, drug development, drug discovery, and customized medicine applications are being driven by 3D cell cultures. To understand the full potential of the technology, researchers can operate more efficiently with complex reagents and precious cells with the aid of high throughput, automated liquid handling solutions.
Biopharmaceutical companies hold the highest market share value of 27.4% during the year 2021. Growing drug development activities propelled by the rising demand for personalized medicine will propel this segment in terms of growth during the projected years. With the standardization of laboratory protocols, as well as the utilization of automated systems for process control technologies during the production process, this segment gains a higher share among the rest of the end users within the global market.
Key players in the market present novel solutions for the lab automation processes for cell biology systems. Moreover, with increasing approvals from the regulatory authorities for software-based total lab automation systems, the key players are presented with an opportunistic outlook for growth during the forecast period.
Similarly, recent developments related to companies manufacturing automated cell biology systems have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2015 to 2021 |
| Market Analysis | US$ Billion for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Product, Cell Culture, Application, End User, and Region |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The global automated cell biology systems market stands at US$ 14.1 Billion in 2022 and is set to expand 2.4X over the next ten years.
The automated cell biology systems market is expected to reach US$ 33.5 Billion by end of 2032 at a CAGR of 9.0%.
The growing geriatric population, the rising burden of chronic and infectious diseases, and rising Research and Development on novel biopharmaceuticals are some of the key trends in this market.
By region, North America holds the highest market share of around 37.4% by value, in 2021, in the global automated cell biology systems market.
Europe is projected to grow with a CAGR of 7.5% during the forecast period.
The USA, Germany, India, China, and the United Kingdom are the top five countries, which are expected to drive demand in the automated cell biology systems market.
Thermo Fisher Scientific, Corning Incorporated, Merck KGaA, Lonza, Sartorius AG, Hitachi. Ltd, Nanoentek, ChemoMetec, Danaher Corporation, Agilent Technologies, Perkin Elmer (Nexcelom Bioscience LLC.), F. Hoffmann-La Roche AG, SHIMADZU CORPORATION, Bio-Rad Laboratories, Miltenyi Biotec, Sinfonia Technology, SHIBUYA CORPORATION, Advanced Instruments, Cell Culture Company, LLC, BD, and Hamilton Company, are some of the key players in the automated cell biology systems industry.
From 2015 to 2021, the market for automated cell biology systems expanded at the rate of 6.6% CAGR.
The automated cell biology systems market in South Asia is expected to grow at 12.3% CAGR during the forecast period.
East Asia is set to present lucrative growth at a CAGR of 13.1% during the forecasted years.
The automated cell biology systems market in South Asia is expected to grow at 12.3% CAGR during the forecast period.
East Asia is set to present lucrative growth at a CAGR of 13.1% during the forecasted years.
1. Executive Summary | Automated Cell Biology Systems Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Innovation / Development Trends 4. Key Success Factors 4.1. Product Adoption Analysis 4.2. Regulatory Landscape 4.3. Reimbursement Scenario 4.4. PESTEL Analysis 4.5. Porter’s Analysis 4.6. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Outlook 5.1.3. Global Market Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Increasing Prevalence of Chronic and Infectious Diseases 5.2.2. Growing Elderly Population 5.2.3. Growing Efforts on Stem Cell Research 5.2.4. Increasing Demand for Gene Therapies 5.2.5. Rising Biopharmaceutical Production 5.2.6. Growing Investments in R&D 5.2.7. Rising Adoption of Automated Systems for Bulk Manufacturing 5.2.8. Increasing Focus on New Drug Discovery and Development 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. By Product 6.1.2. By Application 6.1.3. By Cell Culture 6.1.4. By End User 6.1.5. By Country 6.2. 2021 Market Scenario 7. Global Market Volume (Units) Analysis 2015 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Volume (Units) Analysis, 2015 to 2021 7.2. Current and Future Market Volume (Units) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 8. Global Market - Pricing Analysis 8.1. Regional Pricing Analysis By Product 8.2. Pricing Break-up 8.2.1. Manufacturer-Level Pricing 8.2.2. Distributor Level Pricing 8.3. Global Average Pricing Analysis Benchmark 8.4. Pricing Assumptions 9. Global Market Demand (in Value or Size in US$ Million) Analysis 2015 to 2021 and Forecast, 2022 to 2032 9.1. Historical Market Value (US$ Million) Analysis, 2015 to 2021 9.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 9.2.1. Y-o-Y Growth Trend Analysis 9.2.2. Absolute $ Opportunity Analysis 10. Global Market Analysis, By Product 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Product, 2015 to 2021 10.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Product, 2022 to 2032 10.3.1. Cell Culture Process Automatization Instrument or Robot (Multiple Function) 10.3.2. Automated Bioreactor (Single or Multiple Function) 10.3.3. Automated Cell Culture Media Exchange System (Single Function) 10.3.4. Automated Culture Media Analyzer (Single Function) 10.3.5. Automated Cell Wash-and-Concentrate System (Single Function) 10.3.6. Automated Cell Counter (Single Function) 10.3.7. Automated Fill and Finish System (Single Function) 10.3.8. Automated Cell Storage Equipment (Single Function) 10.3.9. Management Software 10.4. Market Attractiveness Analysis By Product 11. Global Market Analysis, By Cell Culture 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Cell Culture, 2015 to 2021 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Cell Culture, 2022 to 2032 11.3.1. Finite Cell Line Cultures 11.3.2. Infinite Cell Line Cultures 11.4. Market Attractiveness Analysis By Cell Culture 12. Global Market Analysis, By Application 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis, By Application, 2015 to 2021 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2022 to 2032 12.3.1. Cell Therapy 12.3.2. Drug Development 12.3.3. Stem Cell Research 12.3.4. Regenerative Medicine 12.4. Market Attractiveness Analysis By Application 13. Global Market Analysis, By End User 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Million) Analysis, By End User, 2015 to 2021 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2022 to 2032 13.3.1. Mega Pharmaceutical companies 13.3.2. Biopharmaceutical companies 13.3.3. CDMOs/CMOs 13.3.4. Research organizations 13.3.5. Academic institutes 13.4. Market Attractiveness Analysis By End User 14. Global Market Analysis, By Region 14.1. Introduction 14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Region, 2015 to 2021 14.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032 14.3.1. North America 14.3.2. Latin America 14.3.3. Europe 14.3.4. East Asia 14.3.5. South Asia 14.3.6. Oceania 14.3.7. Middle East and Africa (MEA) 14.4. Market Attractiveness Analysis By Region 15. North America Market Analysis 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2015 to 2021 15.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032 15.3.1. By Country 15.3.1.1. USA 15.3.1.2. Canada 15.3.2. By Product 15.3.3. By Application 15.3.4. By Cell Culture 15.3.5. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Product 15.4.3. By Cell Culture 15.4.4. By Application 15.4.5. By End User 15.5. Market Trends 15.6. Drivers and Restraints - Impact Analysis 15.7. Country-Level Analysis & Forecast 15.7.1. USA Market Analysis 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Product 15.7.1.2.2. By Cell Culture 15.7.1.2.3. By Application 15.7.1.2.4. By End User 15.7.2. Canada Market Analysis 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Product 15.7.2.2.2. By Cell Culture 15.7.2.2.3. By Application 15.7.2.2.4. By End User 16. Latin America Market Analysis 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2015 to 2021 16.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032 16.3.1. By Country 16.3.1.1. Mexico 16.3.1.2. Brazil 16.3.1.3. Argentina 16.3.1.4. Rest of Latin America 16.3.2. By Product 16.3.3. By Cell Culture 16.3.4. By Application 16.3.5. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Product 16.4.3. By Cell Culture 16.4.4. By Application 16.4.5. By End User 16.5. Market Trends 16.6. Drivers and Restraints - Impact Analysis 16.7. Country-Level Analysis & Forecast 16.7.1. Mexico Market Analysis 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Product 16.7.1.2.2. By Cell Culture 16.7.1.2.3. By Application 16.7.1.2.4. By End User 16.7.2. Brazil Market Analysis 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Product 16.7.2.2.2. By Cell Culture 16.7.2.2.3. By Application 16.7.2.2.4. By End User 16.7.3. Argentina Market Analysis 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Product 16.7.3.2.2. By Cell Culture 16.7.3.2.3. By Application 16.7.3.2.4. By End User 17. Europe Market Analysis 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2015 to 2021 17.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032 17.3.1. By Country 17.3.1.1. Germany 17.3.1.2. Italy 17.3.1.3. France 17.3.1.4. United Kingdom 17.3.1.5. Spain 17.3.1.6. BENELUX 17.3.1.7. Russia 17.3.1.8. Rest of Europe 17.3.2. By Product 17.3.3. By Cell Culture 17.3.4. By Application 17.3.5. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Product 17.4.3. By Cell Culture 17.4.4. By Application 17.4.5. By End User 17.5. Market Trends 17.6. Drivers and Restraints - Impact Analysis 17.7. Country-Level Analysis & Forecast 17.7.1. Germany Market Analysis 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Product 17.7.1.2.2. By Cell Culture 17.7.1.2.3. By Application 17.7.1.2.4. By End User 17.7.2. Italy Market Analysis 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Product 17.7.2.2.2. By Cell Culture 17.7.2.2.3. By Application 17.7.2.2.4. By End User 17.7.3. France Market Analysis 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Product 17.7.3.2.2. By Cell Culture 17.7.3.2.3. By Application 17.7.3.2.4. By End User 17.7.4. United Kingdom Market Analysis 17.7.4.1. Introduction 17.7.4.2. Market Analysis and Forecast by Market Taxonomy 17.7.4.2.1. By Product 17.7.4.2.2. By Cell Culture 17.7.4.2.3. By Application 17.7.4.2.4. By End User 17.7.5. Spain Market Analysis 17.7.5.1. Introduction 17.7.5.2. Market Analysis and Forecast by Market Taxonomy 17.7.5.2.1. By Product 17.7.5.2.2. By Cell Culture 17.7.5.2.3. By Application 17.7.5.2.4. By End User 17.7.6. BENELUX Market Analysis 17.7.6.1. Introduction 17.7.6.2. Market Analysis and Forecast by Market Taxonomy 17.7.6.2.1. By Product 17.7.6.2.2. By Cell Culture 17.7.6.2.3. By Application 17.7.6.2.4. By End User 17.7.7. Russia Market Analysis 17.7.7.1. Introduction 17.7.7.2. Market Analysis and Forecast by Market Taxonomy 17.7.7.2.1. By Product 17.7.7.2.2. By Cell Culture 17.7.7.2.3. By Application 17.7.7.2.4. By End User 18. East Asia Market Analysis 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2015 to 2021 18.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032 18.3.1. By Country 18.3.1.1. China 18.3.1.2. Japan 18.3.1.3. South Korea 18.3.2. By Product 18.3.3. By Cell Culture 18.3.4. By Application 18.3.5. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Cell Culture 18.4.3. By Product 18.4.4. By Application 18.4.5. By End User 18.5. Market Trends 18.6. Drivers and Restraints - Impact Analysis 18.7. Country-Level Analysis & Forecast 18.7.1. China Market Analysis 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Product 18.7.1.2.2. By Cell Culture 18.7.1.2.3. By Application 18.7.1.2.4. By End User 18.7.2. Japan Market Analysis 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Product 18.7.2.2.2. By Cell Culture 18.7.2.2.3. By Application 18.7.2.2.4. By End User 18.7.3. South Korea Market Analysis 18.7.3.1. Introduction 18.7.3.2. Market Analysis and Forecast by Market Taxonomy 18.7.3.2.1. By Product 18.7.3.2.2. By Cell Culture 18.7.3.2.3. By Application 18.7.3.2.4. By End User 19. South Asia Market Analysis 19.1. Introduction 19.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2015 to 2021 19.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032 19.3.1. By Country 19.3.1.1. India 19.3.1.2. Indonesia 19.3.1.3. Malaysia 19.3.1.4. Thailand 19.3.1.5. Rest of South Asia 19.3.2. By Product 19.3.3. By Cell Culture 19.3.4. By Application 19.3.5. By End User 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Cell Culture 19.4.3. By Product 19.4.4. By Application 19.4.5. By End User 19.5. Market Trends 19.6. Drivers and Restraints - Impact Analysis 19.7. Country-Level Analysis & Forecast 19.7.1. India Market Analysis 19.7.1.1. Introduction 19.7.1.2. Market Analysis and Forecast by Market Taxonomy 19.7.1.2.1. By Product 19.7.1.2.2. By Cell Culture 19.7.1.2.3. By Application 19.7.1.2.4. By End User 19.7.2. Indonesia Market Analysis 19.7.2.1. Introduction 19.7.2.2. Market Analysis and Forecast by Market Taxonomy 19.7.2.2.1. By Product 19.7.2.2.2. By Cell Culture 19.7.2.2.3. By Application 19.7.2.2.4. By End User 19.7.3. Malaysia Market Analysis 19.7.3.1. Introduction 19.7.3.2. Market Analysis and Forecast by Market Taxonomy 19.7.3.2.1. By Product 19.7.3.2.2. By Cell Culture 19.7.3.2.3. By Application 19.7.3.2.4. By End User 19.7.4. Thailand Market Analysis 19.7.4.1. Introduction 19.7.4.2. Market Analysis and Forecast by Market Taxonomy 19.7.4.2.1. By Product 19.7.4.2.2. By Cell Culture 19.7.4.2.3. By Application 19.7.4.2.4. By End User 20. Oceania Market Analysis 20.1. Introduction 20.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2015 to 2021 20.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032 20.3.1. By Country 20.3.1.1. Australia 20.3.1.2. New Zealand 20.3.2. By Product 20.3.3. By Cell Culture 20.3.4. By Application 20.3.5. By End User 20.4. Market Attractiveness Analysis 20.4.1. By Country 20.4.2. By Product 20.4.3. By Cell Culture 20.4.4. By Application 20.4.5. By End User 20.5. Key Market Participants - Intensity Mapping 20.6. Drivers and Restraints - Impact Analysis 20.7. Country-Level Analysis & Forecast 20.7.1. Australia Market Analysis 20.7.1.1. Introduction 20.7.1.2. Market Analysis and Forecast by Market Taxonomy 20.7.1.2.1. By Product 20.7.1.2.2. By Cell Culture 20.7.1.2.3. By Application 20.7.1.2.4. By End User 20.7.2. New Zealand Market Analysis 20.7.2.1. Introduction 20.7.2.2. Market Analysis and Forecast by Market Taxonomy 20.7.2.2.1. By Product 20.7.2.2.2. By Cell Culture 20.7.2.2.3. By Application 20.7.2.2.4. By End User 21. Middle East and Africa (MEA) Market Analysis 21.1. Introduction 21.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2015 to 2021 21.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, 2022 to 2032 21.3.1. By Country 21.3.1.1. GCC Countries 21.3.1.2. Turkey 21.3.1.3. North Africa 21.3.1.4. South Africa 21.3.1.5. Rest of Middle East and Africa 21.3.2. By Product 21.3.3. By Cell Culture 21.3.4. By Application 21.3.5. By End User 21.4. Market Attractiveness Analysis 21.4.1. By Country 21.4.2. By Product 21.4.3. By Cell Culture 21.4.4. By Application 21.4.5. By End User 21.5. Market Trends 21.6. Drivers and Restraints - Impact Analysis 21.7. Country-Level Analysis & Forecast 21.7.1. GCC Countries Market Analysis 21.7.1.1. Introduction 21.7.1.2. Market Analysis and Forecast by Market Taxonomy 21.7.1.2.1. By Product 21.7.1.2.2. By Cell Culture 21.7.1.2.3. By Application 21.7.1.2.4. By End User 21.7.2. Turkey Market Analysis 21.7.2.1. Introduction 21.7.2.2. Market Analysis and Forecast by Market Taxonomy 21.7.2.2.1. By Product 21.7.2.2.2. By Cell Culture 21.7.2.2.3. By Application 21.7.2.2.4. By End User 21.7.3. South Africa Market Analysis 21.7.3.1. Introduction 21.7.3.2. Market Analysis and Forecast by Market Taxonomy 21.7.3.2.1. By Product 21.7.3.2.2. By Cell Culture 21.7.3.2.3. By Application 21.7.3.2.4. By End User 21.7.4. North Africa Market Analysis 21.7.4.1. Introduction 21.7.4.2. Market Analysis and Forecast by Market Taxonomy 21.7.4.2.1. By Product 21.7.4.2.2. By Cell Culture 21.7.4.2.3. By Application 21.7.4.2.4. By End User 22. Market Structure Analysis 22.1. Market Analysis by Tier of Companies 22.2. Market Share Analysis of Top Players 22.3. Market Presence Analysis 23. Competition Analysis 23.1. Competition Dashboard 23.2. Competition Benchmarking 23.3. Competition Deep Dive 23.3.1. Thermo Fisher Scientific 23.3.1.1. Overview 23.3.1.2. Product Portfolio 23.3.1.3. Sales Footprint 23.3.1.4. Key Financials 23.3.1.5. SWOT Analysis 23.3.1.6. Strategy Overview 23.3.1.6.1. Marketing Strategy 23.3.1.6.2. Product Strategy 23.3.1.6.3. Channel Strategy 23.3.2. Corning Incorporated 23.3.2.1. Overview 23.3.2.2. Product Portfolio 23.3.2.3. Sales Footprint 23.3.2.4. Key Financials 23.3.2.5. SWOT Analysis 23.3.2.6. Strategy Overview 23.3.2.6.1. Marketing Strategy 23.3.2.6.2. Product Strategy 23.3.2.6.3. Channel Strategy 23.3.3. Merck KGaA 23.3.3.1. Overview 23.3.3.2. Product Portfolio 23.3.3.3. Sales Footprint 23.3.3.4. Key Financials 23.3.3.5. SWOT Analysis 23.3.3.6. Strategy Overview 23.3.3.6.1. Marketing Strategy 23.3.3.6.2. Product Strategy 23.3.3.6.3. Channel Strategy 23.3.4. Lonza 23.3.4.1. Overview 23.3.4.2. Product Portfolio 23.3.4.3. Sales Footprint 23.3.4.4. Key Financials 23.3.4.5. SWOT Analysis 23.3.4.6. Strategy Overview 23.3.4.6.1. Marketing Strategy 23.3.4.6.2. Product Strategy 23.3.4.6.3. Channel Strategy 23.3.5. Sartorius AG 23.3.5.1. Overview 23.3.5.2. Product Portfolio 23.3.5.3. Sales Footprint 23.3.5.4. Key Financials 23.3.5.5. SWOT Analysis 23.3.5.6. Strategy Overview 23.3.5.6.1. Marketing Strategy 23.3.5.6.2. Product Strategy 23.3.5.6.3. Channel Strategy 23.3.6. Hitachi. Ltd 23.3.6.1. Overview 23.3.6.2. Product Portfolio 23.3.6.3. Sales Footprint 23.3.6.4. Key Financials 23.3.6.5. SWOT Analysis 23.3.6.6. Strategy Overview 23.3.6.6.1. Marketing Strategy 23.3.6.6.2. Product Strategy 23.3.6.6.3. Channel Strategy 23.3.7. Nanoentek 23.3.7.1. Overview 23.3.7.2. Product Portfolio 23.3.7.3. Sales Footprint 23.3.7.4. Key Financials 23.3.7.5. SWOT Analysis 23.3.7.6. Strategy Overview 23.3.7.6.1. Marketing Strategy 23.3.7.6.2. Product Strategy 23.3.7.6.3. Channel Strategy 23.3.8. ChemoMetec 23.3.8.1. Overview 23.3.8.2. Product Portfolio 23.3.8.3. Sales Footprint 23.3.8.4. Key Financials 23.3.8.5. SWOT Analysis 23.3.8.6. Strategy Overview 23.3.8.6.1. Marketing Strategy 23.3.8.6.2. Product Strategy 23.3.8.6.3. Channel Strategy 23.3.9. Danaher corporation 23.3.9.1. Overview 23.3.9.2. Product Portfolio 23.3.9.3. Sales Footprint 23.3.9.4. Key Financials 23.3.9.5. SWOT Analysis 23.3.9.6. Strategy Overview 23.3.9.6.1. Marketing Strategy 23.3.9.6.2. Product Strategy 23.3.9.6.3. Channel Strategy 23.3.10. Agilent Technologies 23.3.10.1. Overview 23.3.10.2. Product Portfolio 23.3.10.3. Sales Footprint 23.3.10.4. Key Financials 23.3.10.5. SWOT Analysis 23.3.10.6. Strategy Overview 23.3.10.6.1. Marketing Strategy 23.3.10.6.2. Product Strategy 23.3.10.6.3. Channel Strategy 23.3.11. Perkin Elmer (Nexcelom Bioscience LLC.) 23.3.11.1. Overview 23.3.11.2. Product Portfolio 23.3.11.3. Sales Footprint 23.3.11.4. Key Financials 23.3.11.5. SWOT Analysis 23.3.11.6. Strategy Overview 23.3.11.6.1. Marketing Strategy 23.3.11.6.2. Product Strategy 23.3.11.6.3. Channel Strategy 23.3.12. F. Hoffmann-La Roche AG 23.3.12.1. Overview 23.3.12.2. Product Portfolio 23.3.12.3. Sales Footprint 23.3.12.4. Key Financials 23.3.12.5. SWOT Analysis 23.3.12.6. Strategy Overview 23.3.12.6.1. Marketing Strategy 23.3.12.6.2. Product Strategy 23.3.12.6.3. Channel Strategy 23.3.13. SHIMADZU CORPORATION 23.3.13.1. Overview 23.3.13.2. Product Portfolio 23.3.13.3. Sales Footprint 23.3.13.4. Key Financials 23.3.13.5. SWOT Analysis 23.3.13.6. Strategy Overview 23.3.13.6.1. Marketing Strategy 23.3.13.6.2. Product Strategy 23.3.13.6.3. Channel Strategy 23.3.14. Bio-Rad Laboratories 23.3.14.1. Overview 23.3.14.2. Product Portfolio 23.3.14.3. Sales Footprint 23.3.14.4. Key Financials 23.3.14.5. SWOT Analysis 23.3.14.6. Strategy Overview 23.3.14.6.1. Marketing Strategy 23.3.14.6.2. Product Strategy 23.3.14.6.3. Channel Strategy 23.3.15. Miltenyi Biotec 23.3.15.1. Overview 23.3.15.2. Product Portfolio 23.3.15.3. Sales Footprint 23.3.15.4. Key Financials 23.3.15.5. SWOT Analysis 23.3.15.6. Strategy Overview 23.3.15.6.1. Marketing Strategy 23.3.15.6.2. Product Strategy 23.3.15.6.3. Channel Strategy 23.3.16. Sinfonia Technology 23.3.16.1. Overview 23.3.16.2. Product Portfolio 23.3.16.3. Sales Footprint 23.3.16.4. Key Financials 23.3.16.5. SWOT Analysis 23.3.16.6. Strategy Overview 23.3.16.6.1. Marketing Strategy 23.3.16.6.2. Product Strategy 23.3.16.6.3. Channel Strategy 23.3.17. SHIBUYA CORPORATION 23.3.17.1. Overview 23.3.17.2. Product Portfolio 23.3.17.3. Sales Footprint 23.3.17.4. Key Financials 23.3.17.5. SWOT Analysis 23.3.17.6. Strategy Overview 23.3.17.6.1. Marketing Strategy 23.3.17.6.2. Product Strategy 23.3.17.6.3. Channel Strategy 23.3.18. Advanced Instruments 23.3.18.1. Overview 23.3.18.2. Product Portfolio 23.3.18.3. Sales Footprint 23.3.18.4. Key Financials 23.3.18.5. SWOT Analysis 23.3.18.6. Strategy Overview 23.3.18.6.1. Marketing Strategy 23.3.18.6.2. Product Strategy 23.3.18.6.3. Channel Strategy 23.3.19. Cell Culture Company, LLC 23.3.19.1. Overview 23.3.19.2. Product Portfolio 23.3.19.3. Sales Footprint 23.3.19.4. Key Financials 23.3.19.5. SWOT Analysis 23.3.19.6. Strategy Overview 23.3.19.6.1. Marketing Strategy 23.3.19.6.2. Product Strategy 23.3.19.6.3. Channel Strategy 23.3.20. BD 23.3.20.1. Overview 23.3.20.2. Product Portfolio 23.3.20.3. Sales Footprint 23.3.20.4. Key Financials 23.3.20.5. SWOT Analysis 23.3.20.6. Strategy Overview 23.3.20.6.1. Marketing Strategy 23.3.20.6.2. Product Strategy 23.3.20.6.3. Channel Strategy 23.3.21. Hamilton Company 23.3.21.1. Overview 23.3.21.2. Product Portfolio 23.3.21.3. Sales Footprint 23.3.21.4. Key Financials 23.3.21.5. SWOT Analysis 23.3.21.6. Strategy Overview 23.3.21.6.1. Marketing Strategy 23.3.21.6.2. Product Strategy 23.3.21.6.3. Channel Strategy 24. Assumptions and Acronyms Used 25. Research Methodology
Explore Healthcare Insights
View Reports
Automated Cell Biology Systems Market
